Jean-Paul Clozel, Idorsia CEO (Patrick Straub/Keystone via AP Images)
Just months after its first FDA approval, Idorsia dumps binge-eating drug candidate after PhII fail
Idorsia got a potential blockbuster drug approval back in January — the first approval since the small Swiss biotech spun out in 2017. And while a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
